Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

EAST HANOVER, N.J., Dec. 3, 2016 /PRNewswire/ -- Findings from a Novartis clinical trial (ELIANA) evaluating efficacy and safety of CTL019, an investigational chimeric antigen receptor T cell (CAR T) therapy, in relapsed/refractory (r/r) pediatric and young adult patients with B-cell...